Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Global Market Opportunities And Strategies To 2035

Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Definition

Exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics refer to the products and services used to diagnose, monitor, and manage a digestive disorder in which the pancreas fails to secrete sufficient digestive enzymes, primarily lipase, amylase, and protease into the small intestine. This deficiency results in impaired digestion and malabsorption of fats, proteins, and carbohydrates, leading to symptoms such as steatorrhea, weight loss, abdominal discomfort, bloating, and nutritional deficiencies. The EPI therapeutics and diagnostics market consist of sales by entities (organizations, sole traders and partnerships) of EPI therapeutics and diagnostics serves pediatric, adult, and geriatric populations affected by underlying conditions such as chronic pancreatitis, pancreatic cancer, diabetes, and post-pancreatectomy status. These therapeutic and diagnostic solutions are used when patients present with clinical signs of malabsorption or when pancreatic disorders are suspected or confirmed. Management is typically long-term and often lifelong, depending on disease etiology.

Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Segmentation The exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market is segmented by type, by distribution channel and by end user.

By Type –
The Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics market is segmented by type into:

• a) Therapies
• b) Diagnostic

The therapies market was the largest segment of the EPI therapeutics and diagnostics market segmented by type, accounting for 74.8% or $4,573.4 million of the total in 2025. Going forward, the diagnostics segment is expected to be the fastest growing segment in the EPI therapeutics and diagnostics market segmented by type, at a CAGR of 7.8% during 2025-2030.

By Distribution Channel –
The Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics market is segmented by distribution channel into:

• a) Direct Tender
• b) Retail Pharmacy
• c) Third-Party Distributor
• d) Recycled And Sustainable Materials
• e) Other Distribution Channels

The direct tender market was the largest segment of the EPI therapeutics and diagnostics market segmented by distribution channel, accounting for 50.1% or $3,063.5 million of the total in 2025. Going forward, the other distribution channels segment is expected to be the fastest growing segment in the EPI therapeutics and diagnostics market segmented by distribution channel, at a CAGR of 9.7% during 2025-2030.

By End User –
The Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics market is segmented by end user into:

1. a) Hospitals
2. b) Specialty Clinics
3. c) Homecare
4. d) Diagnostic Centers
5. e) Research And Academic Institutes
6. f) Other End Users

The hospitals market was the largest segment of the EPI therapeutics and diagnostics market segmented by end user, accounting for 28.7% or $1,754.9 million of the total in 2025. Going forward, the homecare segment is expected to be the fastest growing segment in the EPI therapeutics and diagnostics market segmented by end user, at a CAGR of 8.5% during 2025-2030.

By Geography - The Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics market is segmented by geography into:

o Asia Pacific
• China
• India
• Japan
• Australia
• Taiwan
• South Korea
o South East Asia
• Indonesia
o North America
• USA
• Canada
o South America
• Brazil
o Western Europe
• France
• Germany
• UK
• Italy
• Spain
o Eastern Europe
• Russia
o Middle East
o Africa

North America was the largest region in the EPI therapeutics and diagnostics market, accounting for 40.8% or $2,493.3 million of the total in 2025. It was followed by Asia Pacific, Western Europe and then the other regions. Going forward, the fastest-growing regions in the EPI therapeutics and diagnostics market will be Asia Pacific and Western Europe where growth will be at CAGRs of 9.3% and 6.6% respectively. These will be followed by Eastern Europe and North America where the markets are expected to grow at CAGRs of 6.3% and 6.1% respectively.

Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Drivers

The key drivers of the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market include: Rising Global Prevalence Of Pancreatic Disorders The rising global prevalence of pancreatic disorders is expected to be a key driver propelling growth in the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market. As pancreatic diseases such as pancreatic cancer and chronic pancreatitis become increasingly common worldwide, healthcare systems are witnessing a growing number of patients experiencing impaired pancreatic function and digestive enzyme deficiencies. The growing burden of pancreatic diseases is expanding the number of patients requiring clinical diagnosis, enzyme replacement therapy, and ongoing medical management. The growth in rising global prevalence of pancreatic disorders growth during the forecast period in 2025 is 1.8%.

Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Restraints

The key restraints on the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market include: High Underdiagnosis And Misdiagnosis Rates High underdiagnosis and misdiagnosis rates are expected to restrict the growth of the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market. As the symptoms of EPI, including diarrhea, weight loss, bloating, and malnutrition, often overlap with other gastrointestinal disorders, accurate identification of the condition becomes challenging in routine clinical practice. The similarity of symptoms with diseases such as irritable bowel syndrome and celiac disease increases the likelihood that many patients remain undiagnosed or incorrectly diagnosed for extended periods. The presence of high underdiagnosis and misdiagnosis rates can delay appropriate treatment and limit patient access to pancreatic enzyme therapies and diagnostic testing. Growth affected by high underdiagnosis and misdiagnosis rates during the forecast period in 2025 is -1.5%.

Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Competitive Landscape

Major Competitors are:

AbbVie Inc. (Creon)

Nestlé Health Science SA (Zenpep)

Abbott Laboratories

Nordmark Arzneimittel GmbH & Co. KG

DiaSorin S.p.A.

Other Competitors Include:

Organon Group of Companies

VIVUS Inc.

Quest Diagnostics Incorporated

Genova Diagnostics

Alcresta Therapeutics Inc.

Genetic Pharma

Digestive Care, Inc.

EagleBio

Shanghai Fosun Pharmaceutical (Group) Co. Ltd.

Janssen Pharmaceuticals (Johnson & Johnson subsidiary)

Bioserv Diagnostic

Adalvo Limited

ScheBo Biotech AG

Alfasigma S.p.A.

Siemens Healthineers

Viatris Inc.

First Wave BioPharma Inc. (Now Entero Therapeutics)

Codexis Inc.

BÜHLMANN Laboratories AG

Labcorp

Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Trends

Major trends shaping the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market include: Enhanced Affordability Program Supports Commercially Insured EPI Patients Major companies operating in the EPI therapeutics and diagnostics market are focusing on the Patient Cost-Sharing Relief Program rolled out for pancreatic enzyme replacement therapy. The high out-of-pocket costs associated with chronic enzyme therapy often lead to cost-related non-adherence, where patients skip doses or forego medication entirely to save money, resulting in severe health consequences like malnutrition and weight loss. By rolling out these assistance programs, manufacturers aim to bridge the gap between insurance coverage and actual affordability, ensuring patients receive the consistent treatment necessary for managing Exocrine Pancreatic Insufficiency (EPI) effectively. For instance, in February 2026, Vivus, a US-based small pharmaceutical company, announced a new copay assistance program for PANCREAZE®, its porcine-derived pancreatic enzyme replacement therapy (PERT) used to treat exocrine pancreatic insufficiency (EPI). In this chronic condition, the pancreas fails to produce sufficient digestive enzymes for proper food breakdown. The program offers eligible commercially insured patients as little as $0 per prescription fill, with up to $2,000 in copay or out-of-pocket cost support per fill and a maximum annual benefit of $3,500, aimed at reducing financial barriers to access to long-term therapy. Advancements in Next-Generation Pancreatic Enzyme Replacement Therapies (PERT)

Opportunities And Recommendations In The Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market

Opportunities – The top opportunities in the EPI therapeutics and diagnostics market segmented by type will arise in the therapies segment, which will gain $1,811.3 million of global annual sales by 2030. The top opportunities in the EPI therapeutics and diagnostics market segmented by distribution channel will arise in the direct tender segment, which will gain $1,071.7 million of global annual sales by 2030. The top opportunities in the EPI therapeutics and diagnostics market segmented by end user will arise in the specialty clinics segment, which will gain $771.7 million of global annual sales by 2030. The EPI therapeutics and diagnostics market size will gain the most in the USA at $787.0 million. Recommendations- To take advantage of the opportunities, The Business Research Company recommends the EPI therapeutics and diagnostics companies to focus on expanding patient cost relief programs to improve adherence and outcomes, focus on advancing next-generation pert formulations for improved delivery and compliance, focus on expanding diagnostics segment for high-growth opportunities, expand in emerging markets, continue to focus on developed markets, focus on expanding multi-channel distribution for epi therapeutics and diagnostics, focus on strategic partnerships to accelerate novel lipase therapy development, focus on value based tiered pricing and access alignment, focus on targeted disease awareness and early diagnosis, focus on data-driven multichannel engagement and stakeholder alignment, focus on expanding homecare segment for sustained growth, focus on scaling digital and alternative distribution channels.